**To the editor:**

Primary testicular lymphoma (PTL) is a rare, clinically aggressive type of extra nodal lymphoma \[[@CR1]\]. Approximately 80--98% of PTL cases are diagnosed as diffuse large B-cell lymphoma (DLBCL), a common heterogeneous type of non-Hodgkin's lymphoma (NHL) \[[@CR2]\]. PTL features a high risk of relapse in the central nervous system (CNS) and contralateral testis, directly leading to a poor outcome in the patients \[[@CR3]\]. In recent years, the addition of radiotherapy, full-course chemotherapy and CNS-directed prophylaxis and rituximab have greatly improved the prognosis of DLBCL patients; however, the prognosis for PTL remains poor \[[@CR4]\]. Previous studies reported that B symptoms, advanced Ann Arbor stage (III/IV), and extra nodal involvement are poor prognostic markers for PTL \[[@CR5]\]. MYD88 and CD79B mutations are frequently observed in PTL, but no prognostic impact was observed \[[@CR6]\]. The gene mutation landscape and the prognosis of PTL remain poorly defined. In addition, information on different mutations in PTL is not available.

In our study, we used NGS to clarify the mutation landscape of PTL in 90 patients, who attended the First Affiliated Hospital of Soochow University and the First Affiliated Hospital of Nantong University between January 2007 and July 2018. This study was approved by the Ethics committee of the First Affiliated Hospital of Soochow University in accordance to the Declaration of Helsinki. Sixty-six patients (73%) received an anthracyline-based chemotherapy, usually CHOP regimen. Twenty-four patients (27%) were simultaneously treated with rituximab. The median chemotherapy course was six courses. Twelve patients received irradiation aimed at the contralateral testis, and no patient received head irradiation. OS was estimated using the Kaplan-Meier method. The two-sided level of significance was *p* \< 0.05. Statistical analyses were performed using SPSS 23.0. The follow-up was updated on August 31, 2019, with a median follow-up time of 36 (1--120) months. Fourteen patients (15.5%) were lost to follow-up (Supplementary Table [1](#MOESM1){ref-type="media"} and [2](#MOESM1){ref-type="media"}).

Patients'DNA was extracted from paraffin-embedded tissues in accordance to the manufacturer's protocol and were sequenced on an Illumina Hiseq 2000 instrument using a targeted panel covering 446 genes (Table [1](#MOESM1){ref-type="media"} in Supplementary Appendix). We identified 1326 mutations involving 311 genes or regions in 90 PTL patients. MYD88 mutations were the most frequently observed mutation, occurring in 75.6% (68/90) patients. Other commonly mutated genes were PIM1 (71.1%), TBL1XR1 (37.8%), KMT2D (37.8%) and KMT2C (34.4%) (Fig. [1](#Fig1){ref-type="fig"}a, supplementary information is given in Table [3](#MOESM1){ref-type="media"}). There was a positive correlation between TBL1XR1 and PIM1/BTG2 mutations (*r* = 0.244 and *r* = 0.247, respectively) (Table [1](#Tab1){ref-type="table"}). PTL patients with TBL1XR1 mutation, irrespective of treatment therapy, had an inferior OS than TBL1XR1 WT patients (*p* = 0.045, HR 1.854, 95%CI 1.004--3.442) (Fig. [1](#Fig1){ref-type="fig"}b). Moreover, patients carrying this mutation, treated with CHOP regimen, also had poorer OS (*p* = 0.019, HR 2.378, 95%CI 1.121--5.045) (Fig. [1](#Fig1){ref-type="fig"}c). Fig. 1**a** Landscape of Driver Mutations in primary testicular diffuse large B-cell lymphoma; **b** Overall survival rate in all patients with TBL1XR1 mutation or not; **c** Overall survival rate in patients treated with CHOP regimen with TBL1XR1 mutation or not; **d** Overall survival rate in all patients with invasion or notTable 1Baseline characteristics of the patientsTBL1XR1 mutation\
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TBL1XR1, also known as TBLR1, is an evolutionarily conserved protein that has high structural and functional similarities. It plays an important role in activation of multiple intracellular signaling pathways, such as Wnt-β-catenin, NF-κB, and Notch signaling pathways \[[@CR7]\]. Dysregulation of TBL1XR1 has been observed in lots of neoplastic conditions \[[@CR8]\]. TBL1XR1 is preferentially expressed in human CD34 + CD38- cells and vital for stem cell balancing. In B-cell acute lymphoblastic leukemia, function loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin, resulting in glucocorticoid resistance \[[@CR9]\].

In addition, patients with TBL1XR1 mutation were prone to have more intensive infiltration of tumors (*p* = 0.025, x^2^ = 4.890). This finding is consistent with a previous study, which reported that abnormal regulation of TBL1XR1 is associated with advanced tumor stage, metastasis, and poor prognosis in most solid tumors \[[@CR10]\]. Patients with tumor infiltration had poorer outcomes, and there was a statistical difference between TBL1XR1 mutation and WT groups (*p* = 0.002, HR 2.568, 95%CI 1.382--4.772) (Fig. [1](#Fig1){ref-type="fig"}d). OS of patients with TBL1XR1 mutation treated with CHOP regimen was 11.5% whereas OS of patients with TBL1XR1 mutation treated with R-CHOP regimen was 100% (6/6). Thus, we speculate that rituximab may improve the prognosis of patients with TBL1XR1 mutations, but this needs to be further studied by more patients.

In conclusion, we found that TBL1XR1 is commonly mutated in PTL. Patients with TBL1XR1 mutations have lower OS, partly due to greater invasion and infiltration of tumors. Therefore, TBL1XR1 mutation can be used as an indicator to predict the prognosis of PTL and a promising new target for treatment of PTL in future.
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